Journal article
Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis
- Abstract:
-
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.
METHODS: This was a collaborative trial-level meta-analysis from the SGLT2i Meta-analysis Cardio-Renal Trialists Consortium, which includes all phase 3, placebo-controlled, outcomes trials of SGLT2i ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.0MB, Terms of use)
-
- Publisher copy:
- 10.1161/circulationaha.124.069568
Authors
+ Australian National Health and Medical Research Council
More from this funder
- Grant:
- 2026621
- Programme:
- Emerging Leader Investigator Grant
- Publisher:
- American Heart Association
- Journal:
- Circulation More from this journal
- Volume:
- 149
- Issue:
- 23
- Pages:
- 1789-1801
- Publication date:
- 2024-04-07
- Acceptance date:
- 2024-03-30
- DOI:
- EISSN:
-
1524-4539
- ISSN:
-
0009-7322
- Pmid:
-
38583093
- Language:
-
English
- Keywords:
- Pubs id:
-
1989269
- Local pid:
-
pubs:1989269
- Deposit date:
-
2024-07-04
- ARK identifier:
Terms of use
- Copyright holder:
- Patel et al.
- Copyright date:
- 2024
- Rights statement:
- © 2024 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
If you are the owner of this record, you can report an update to it here: Report update to this record